Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01806064 · ClinicalTrials.gov registry record · Phase 1
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
A Phase 1 study, sponsored by Tracon Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 173
- Enrollment target
NCT01806064 is a Phase 1 study that was terminated before completion, run by Tracon Pharmaceuticals. The registered enrollment target is 173 participants.
The verdict
NCT01806064, a Phase 1 study, was terminated before completion, sponsored by Tracon Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 173 participants
- Enrollment target
Study Summary
Phase 1b: To evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose axitinib in patients with advanced renal cell carcinoma. Phase 2: To estimate the PFS of patients with advanced or metastatic RCC by RECIST 1.1 criteria in patients treated with axitinib and TRC105 compared to those treated with axitinib alone, following failure of one prior VEGF TKI
Interventions
- DRUG Axitinib
- DRUG TRC105 and Axitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2013-03-08 |
| Est. Completion | 2019-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01806064
The ClinicalTrials.gov registry entry for NCT01806064 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Axitinib is the first listed.
NCT01806064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01806064 about?
NCT01806064 is a clinical study titled "Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma". Phase 1b: To evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose axitinib in patients with advanced renal cell carcinoma. Phase 2: To estimate the PFS of patients with advanced or metastatic RCC by RECIST 1.1 criteria in patients treated ...
What is the current status of trial NCT01806064?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 173 participants. The study started on 2013-03-08. Estimated completion is 2019-06-12.
What interventions are being tested in trial NCT01806064?
The interventions under investigation include: Axitinib (DRUG), TRC105 and Axitinib (DRUG).
Who is sponsoring clinical trial NCT01806064?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.